MANAGEMENT OF PATIENTS WITH HEMOPHILIA A ON EMICIZUMAB PROPHYLACTIC TREATMENT: RECOMMENDATION FROM RUSSIAN EXPERTS

被引：0

作者：

Andreeva, T. A. ^{[1
]}

Zharkov, P. A. ^{[3
]}

Zozulya, N., I ^{[4
]}

Zorenko, V. Yu ^{[4
]}

Konstantinova, V. N. ^{[1
]}

Lebedev, V. V. ^{[2
]}

Mamaev, A. N. ^{[5
]}

Markova, I., V ^{[6
]}

Petrov, V. Yu ^{[7
]}

Polyanskaya, T. Yu ^{[8
]}

Schiller, E. E. ^{[9
]}

机构：

[1] Hematologist Head City Ctr Treatment Patients, City Polyclin 37, St Petersburg 191186, Russia

[2] Childrens Reg Clin Hosp, Head Childrens Reg Oncohematol Ctr, Minist Hlth Krasnodar Reg, Krasnodar 350007, Russia

[3] Dmitriy Rogachev Natl Med Res Ctr Pediat Hematol, Hematologist Consultat Dept, Pediatrician Short Term Treatment Inpatient Dept, Moscow 117997, Russia

[4] Natl Med Res Ctr Hematol, Head Dept Hemostasis Disorders, Moscow 125167, Russia

[5] Natl Med Res Ctr Hematol, Altai Div, Minist Hlth Russian Federat, Moscow 125167, Russia

[6] Raisa Gorbacheva Mem Res Inst Pediat Oncol Hemato, St Petersburg 1999022, Russia

[7] Morozovskaya Childrens City Clin Hosp, Moscow Hlth Dept, Hematologist Hematol Dept, Moscow 119049, Russia

[8] Natl Res Ctr Hematol, Dept Traumatol & Orthoped, Moscow 125167, Russia

[9] Odintsovo Reg Hosp, Head Children Hematol Dept, Odintsovo 143003, Russia

来源：

GEMATOLOGIYA I TRANSFUZIOLOGIYA | 2022年 / 67卷 / 02期

关键词：

emicizumab; hemophilia; factor VIII; factor VIII inhibitor; BISPECIFIC ANTIBODY; INHIBITORS; BLEEDS;

D O I：

10.35754/0234-5730-2022-67-2-267-280

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction. In 2018 emicizumab was approved in Russia for prophylactic treatment in patients with hemophilia A (HA) with inhibitors and in 2019 for patients with severe HA without inhibitors. A significant amount of data has been accumulated from clinical trials and real-world data, which allow us to resolve most of the questions that hematologists may have when to prescribe emicizumab. Aim - to provide information on the management of patients on emicizumab. Results. The recommendations accumulated the currently available information and world experience in the management of patients receiving emicizumab in order to facilitate decision-making when prescribing and using emicizumab. Information on the use of emicizumab in patients with HA with FVIII inhibitors and severe HA without FVIII inhibitors is presented. Possible complications and measures for their prevention and treatment are presented.

引用

页码：267 / 280

页数：14

共 48 条

[41] Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
Parameswaran, R
Shapiro, AD
Gill, JC
Kessler, CM
HAEMOPHILIA, 2005, 11 (02) : 100 - 106
[42] Transfusion-transmitted infections in hemophilia patients who underwent surgical treatment: a study from a single center in north China
Peng, Hui-Ming
Wang, Long-Chao
Zhai, Ji-Liang
Weng, Xi-Sheng
Fen, Bin
Wang, Wei
ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (02) : 308 - 312
[43] Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)
Susen, Sophie
Gruel, Yves
Godier, Anne
Harroche, Annie
Chambost, Herve
Lasne, Dominique
Rauch, Antoine
Roullet, Stephanie
Fontana, Pierre
Goudemand, Jenny
de Maistre, Emmanuel
Chamouard, Valerie
Wibaut, Bndicte
Albaladejo, Pierre
Negrier, Claude
HAEMOPHILIA, 2019, 25 (05) : 731 - 737
[44] ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database
Ogawa, Yoshiyuki
Amano, Kagehiro
Matsuo-Tezuka, Yukari
Okada, Norihiro
Murakami, Yoichi
Nakamura, Takao
Yamaguchi-Suita, Haruko
Nogami, Keiji
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (01) : 44 - 55
[45] Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients
Reipert, Birgit M.
Hofbauer, Christoph J.
Gangadharan, Bagirath
Berg, Verena
Donnachie, Elizabeth
Meeks, Shannon
Mancuso, Maria Elisa
Bowen, Joel
Brown, Deborah L.
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (05)
[46] Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres
Escobar, M.
Maahs, J.
Hellman, E.
Donkin, J.
Forsyth, A.
Hroma, N.
Young, G.
Valentino, L. A.
Tachdjian, R.
Cooper, D. L.
Shapiro, A. D.
HAEMOPHILIA, 2012, 18 (06) : 971 - 981
[47] Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
Tabernero, J.
Velez, L.
Trevino, T. L.
Grothey, A.
Yaeger, R.
Van Cutsem, E.
Wasan, H.
Desai, J.
Ciardiello, F.
Yoshino, T.
Gollerkeri, A.
Maharry, K.
Christy-Bittel, J.
Kopetz, S.
ESMO OPEN, 2021, 6 (06)
[48] Impact of Systematic Joint Examination (Ultrasound, Functional and Physical) on Treatment Management Decisions in Patients With Haemophilia A in France: Final Data From the Prospective, Observational A-MOVE Study
Drillaud, Nicolas
Barbay, Virginie
Valentin, Jean Baptiste
Jailler, Romain
Lebreton, Aurelien
Pan-Petesch, Brigitte
Castet, Sabine Marie
Frotscher, Birgit
Frenzel, Laurent
Jousse-Joulin, Sandrine
Chambost, Herve
Alenas, Mikaela
Fusser, Markus
Gandossi, Corinne
Zidi, Meriem
Mahdout, Oussama
Repesse, Yohann
HAEMOPHILIA, 2025, 31 (02) : 239 - 246

← 1 2 3 4 5 →